A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
Inclusion Criteria:
Exclusion Criteria:
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
Prague, 121 08, Czechia
Århus N, 8200, Denmark
Saint Augustin, North Rhine-Westphalia 53757, Germany
Saitama-shi, Saitama 330 8777, Japan
Bunkyō, Tokyo 113-8519, Japan
Chuo-Ku, Tokyo 104 8560, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Lodz, 91-738, Poland
Bloomsbury, London WC1N 3JH, United Kingdom